Brusatol(鸦胆子苦醇,AbMole,M8710)是一种从植物鸦胆子(Brucea javanica)中分离得到的喹啉类天然化合物,能抑制细胞蛋白的从头合成,并在多种细胞和动物模型中展现出显著的生物学活性。
在细胞实验中,
Brusatol(鸦胆子苦醇,AbMole,M8710)(CAS No.:14907-98-3)以剂量和时间依赖性方式抑制多种癌细胞系的增殖,包括非小细胞肺癌细胞A549、H1650、PC9和HCC827[1],鼻咽癌细胞CNE-1、CNE-2、5-8F和6-10B[2],急性淋巴细胞白血病(ALL)细胞系KOPN-8(B-ALL)、CEM和MOLT-4(T-ALL)[3],胶质瘤细胞LN229和U251[4]。
Brusatol(鸦胆子苦醇)作用机制涉及多个通路,首先
Brusatol(鸦胆子苦醇,AbMole,M8710)可抑制核因子E2相关因子2(Nrf2)通路,从而削弱细胞的抗氧化能力,导致活性氧(ROS)显著积累[5];
Brusatol(鸦胆子苦醇,AbMole,M8710)(CAS No.:14907-98-3)还能诱导线粒体膜电位下降,激活Caspase-3/7/9及PARP切割,促进线粒体依赖性凋亡[6];引起G0/G1或G2/M期细胞周期阻滞,伴随Cyclin B1、Cdc25c、Cdc2 p34和Cyclin D1等调控蛋白表达改变[3];抑制PI3K/Akt/mTOR信号通路,表现为p-PI3K和p-AKT水平降低,并上调PTEN表达;同时Brusatol(鸦胆子苦醇)还能抑制上皮-间质转化(EMT),上调E-cadherin,下调N-cadherin和vimentin;此外,Brusatol还能促进铁死亡(Ferroptosis),并下调PLK1、SCD1及KLF4/NCK2轴等关键分子。
在动物实验中,
Brusatol(鸦胆子苦醇,AbMole,M8710)在C57BL/6小鼠(高脂饮食模型)中以2周疗程改善葡萄糖耐量和胰岛β细胞功能[7];在裸鼠异种移植模型中,腹腔或尾静脉给药可显著抑制Cal-27(舌鳞癌)[8]、CNE-1(鼻咽癌)、Hucc-T1(ICC)、Bel7404(肝癌)及胶质瘤等肿瘤生长,常用剂量范围为1–5 mg/kg(如1 mg/kg隔日一次或2 mg/kg每日一次);在斑马鱼幼虫模型中,BrusatolBrusatol(鸦胆子苦醇)的LC50为0.010 ± 0.122 ppm,LC90为0.654 ± 0.081 ppm,且高浓度下引起明显形态学损伤[9];药代动力学研究显示,经尾静脉单次给药后,Brusatol在小鼠血浆中迅速清除,但在组织中分布广泛,尤其在部分组织中的浓度可比血浆高10倍以上[10]。
综上,
Brusatol(鸦胆子苦醇,AbMole,M8710)通过多通路、多靶点机制在多种细胞系和啮齿类动物模型中表现出强效的抗增殖、促凋亡、抗迁移及调控细胞命运的作用,是当前肿瘤生物学研究中的重要工具化合物。
参考文献及鸣谢
[1] Xie, J.; Lai, Z.; Zheng, X.; et al. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.
Toxicology 2021,
451, 152680.
[2] Guo, S.; Zhang, J.; Wei, C.; et al. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
Cancer chemotherapy and pharmacology 2020,
85 (6), 1097-1108.
[3] Jorge, J.; Magalhaes, N.; Alves, R.; et al. Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation.
Biomedicines 2022,
10 (9).
[4] Chen, Z.; He, B.; Zhao, J.; et al. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
Phytomedicine : international journal of phytotherapy and phytopharmacology 2022,
104, 154323.
[5] Guo, N.; Zhang, Y.; Yuan, G.; et al. Pharmacokinetics and nephrotoxicity of cisplatin modulated by combination therapy with brusatol.
Frontiers in pharmacology 2026,
17, 1708101.
[6] Huang, C. H.; Wang, F. T.; Chan, W. H. Role of caspase-3-cleaved/activated PAK2 in brusatol-triggered apoptosis of human lung cancer A549 cells.
Toxicology research 2022,
11 (5), 791-803.
[7] Turpaev, K.; Krizhanovskii, C.; Wang, X.; et al. The protein synthesis inhibitor brusatol normalizes high-fat diet-induced glucose intolerance in male C57BL/6 mice: role of translation factor eIF5A hypusination.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019,
33 (3), 3510-3522.
[8] Qi, S.; Li, D.; Deng, F.; et al. Brusatol modulates the Nrf2/GCLC pathway to enhance ferroptosis in the treatment of oral squamous cell carcinoma.
European journal of pharmacology 2025,
1003, 177935.
[9] Sutiningsih, D.; Nurjazuli, N.; Nugroho, D.; et al. Larvicidal Activity of Brusatol Isolated from Brucea javanica (L) Merr on Culex quinquefasciatus.
Iranian journal of public health 2019,
48 (4), 688-696.
[10] Guo, N.; Zhang, X.; Bu, F.; et al. Determination of brusatol in plasma and tissues by LC-MS method and its application to a pharmacokinetic and distribution study in mice.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2017,
1053, 20-26.
细胞实验参考
细胞系:MDA-MB-468 cells
方法: HCECs were pretreated with 15 nM brusatol (Nrf2 inhibitor, Abmole, USA) or 10 µM ZnPP for 1 h prior to TQ treatment. Subsequently, the cells were stimulated with C. albicans conidia for 8 h (PCR) or 24 h
浓度: 15 nM
处理时间:1 h
参考文献:Cytokine. 2023 Dec;172:156375.
* 上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。